Charles Schwab Investment Management Inc. Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Charles Schwab Investment Management Inc. lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 5.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 387,187 shares of the company’s stock after buying an additional 20,346 shares during the period. Charles Schwab Investment Management Inc. owned about 0.60% of Kymera Therapeutics worth $15,577,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in shares of Kymera Therapeutics by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 127,093 shares of the company’s stock valued at $5,113,000 after buying an additional 5,448 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Kymera Therapeutics by 3.0% during the 4th quarter. Rhumbline Advisers now owns 64,157 shares of the company’s stock valued at $2,581,000 after buying an additional 1,861 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company’s stock valued at $552,000 after buying an additional 1,311 shares in the last quarter. KBC Group NV raised its holdings in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares in the last quarter.

Insider Activity

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now owns 54,826 shares in the company, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock worth $455,202 in the last quarter. 15.82% of the stock is owned by company insiders.

Kymera Therapeutics Stock Down 1.9 %

KYMR opened at $33.21 on Friday. The stock has a market cap of $2.16 billion, a PE ratio of -14.19 and a beta of 2.22. The business has a 50 day moving average of $36.90 and a 200-day moving average of $42.44. Kymera Therapeutics, Inc. has a 52 week low of $29.07 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on KYMR. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. Citigroup began coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. HC Wainwright raised their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.